About Eisai Co. Ltd.Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participate in all aspects of the worldwide healthcare system. Eisai employs more than 8,000 people worldwide. For more information, please visit. Eisai Co.
About Inovelon Inovelon is a structurally novel compound a broad-spectrum a broad-spectrum anticonvulsant originally discovered and developed by Novartis Pharma AG. Eisai signed an in – licensing agreement for the global rights to the compound with Novartis in February 2004. In October 2004 the drug for an orphan status by EC adjunctive treatment of LGS, a severe form of in early childhood in early childhood will be granted.– Payers would benefit from 30400000000 $ a year. – Laboratories would benefit from 13100000000 dollars a year. – radiological centers would benefit from by $ 8200000000 a year. – Pharmacies would benefit from by 1.3 billion euros per annum.
The United States to break even in the fifth year after the implementation and reached $ 395,000 in the net return of the its tenth year.. The results of were collected on a 10-year reaction scenario where the vendors to purchase new information systems, Professional, allows a single set of a single set of technical requirements and dates definitions for the transmission and reception of healthcare information.
A year. May save billions of in the U.S. Health sectorexplorer the Center for Code Technology Leadership indicate a standardized means of electronic exchange of medical info for up to lead to annual savings of up to $ 87 billion when full implementation in all health systems, hospitals and doctors.
When the standardized plan was adopted walk would tell.